Abstract
Effective systemic treatment of pancreatic cancer remains a major challenge, with progress hampered by drug resistance and treatment related toxicities. Currently available cytotoxic agents as monotherapy or in combination have provided only a modest survival benefit for patients with advanced disease. Disappointing phase III results with gemcitabine-based combinations in patients with advanced pancreatic cancer might be related to poor efficacy of systemic therapies in unselected patients. Future research strategies should prioritize identification of predictive markers through pharmacogenetic investigations. The individualization of patient treatment through pharmacogenetics may help to improve outcome by maximizing efficacy whilst lowering toxicity. This review provides an update on the pharmacogenetics of pancreatic cancer treatment and its influence on treatment benefits and toxicity.
Keywords: Pancreatic cancer, pharmacogenetics, chemotherapy, therapy, resistance, Gemcitabine, Intra-Tumoral Molecular Determinants, Clinical Outcome, Multi-drug resistant genes, focal adhesion kinase
Current Drug Targets
Title:Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics
Volume: 13 Issue: 6
Author(s): Ross A. Soo, Wei-Peng Yong and Federico Innocenti
Affiliation:
Keywords: Pancreatic cancer, pharmacogenetics, chemotherapy, therapy, resistance, Gemcitabine, Intra-Tumoral Molecular Determinants, Clinical Outcome, Multi-drug resistant genes, focal adhesion kinase
Abstract: Effective systemic treatment of pancreatic cancer remains a major challenge, with progress hampered by drug resistance and treatment related toxicities. Currently available cytotoxic agents as monotherapy or in combination have provided only a modest survival benefit for patients with advanced disease. Disappointing phase III results with gemcitabine-based combinations in patients with advanced pancreatic cancer might be related to poor efficacy of systemic therapies in unselected patients. Future research strategies should prioritize identification of predictive markers through pharmacogenetic investigations. The individualization of patient treatment through pharmacogenetics may help to improve outcome by maximizing efficacy whilst lowering toxicity. This review provides an update on the pharmacogenetics of pancreatic cancer treatment and its influence on treatment benefits and toxicity.
Export Options
About this article
Cite this article as:
A. Soo Ross, Yong Wei-Peng and Innocenti Federico, Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics, Current Drug Targets 2012; 13 (6) . https://dx.doi.org/10.2174/138945012800564068
DOI https://dx.doi.org/10.2174/138945012800564068 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Salivary Genomics, Transcriptomics and Proteomics: The Emerging Concept of the Oral Ecosystem and their Use in the Early Diagnosis of Cancer and other Diseases
Current Genomics Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems
Recent Patents on Anti-Cancer Drug Discovery The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Smell and Taste Disorders Resulting from Cancer and Chemotherapy
Current Pharmaceutical Design Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Approaches for Ear-targeted Delivery Systems in Neurosensory Disorders to avoid Chronic Hearing Loss Mediated Neurological Diseases
CNS & Neurological Disorders - Drug Targets Concentrations of Cd, Cu, Pb and Zn in Blood Serum of Cancer Patients and Comparison with Healthy Person by Atomic Absorption Spectrometry
Current Analytical Chemistry Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry Lanthanides as Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy
Current Cancer Therapy Reviews Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Immunomodulatory Lactoferrin in the Regulation of Apoptosis Modulatory Proteins in Cancer
Protein & Peptide Letters Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Preparation and Biodistribution of Technetium-99m-Labeled Bis- Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia
Medicinal Chemistry Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy
Current Pharmaceutical Design Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry